CSL Limited Enters Exclusive Agreement With Alentis Therapeutics
Oct 5 (Reuters) - CSL Limited CSL.AX:
CSL ENTERS EXCLUSIVE AGREEMENT WITH ALENTIS THERAPEUTICS
TO PAY ALENTIS $355 MILLION UPFRONT AND UP TO $1.2 BILLION IN MILESTONES
ENTERS AGREEMENT WITH ALENTIS TO CO-DEVELOP AND CO-PROMOTE LIXUDEBART
TO FULLY FUND PHASE 2 AND PHASE 3 TRIALS FOR LIXUDEBART
Further company coverage: CSL.AX